TY - JOUR
T1 - Evaluation of Bacterial Polysaccharide Immune Globulin for the Treatment or Prevention of Haemophilus influenzae Type b and Pneumococcal Disease
AU - Siber, George R.
AU - Thompson, Claudette
AU - Raymond Reid, G.
AU - Almeido-Hill, Janné
AU - Zacher, Bonnie
AU - Wolff, Mark
AU - Santosham, Mathuram
PY - 1992/6
Y1 - 1992/6
N2 - A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.
AB - A human hyperimmune globulin termed bacterial polysaccharide immune globulin (BPIG) has been prepared from plasma donors immunized with Haemophilus influenzae type b (Hib), pneumococcal, and meningococcal vaccines. At a dose of 0.5 ml/kg, BPIG increased levels of antibody to Hib by >0.15 µg/ml within 4-6 h and by 2-4 µg/ml at 72 h. Thereafter, antibody declined, with a mean half-life of 27 days. BPIG treatment of Apache infants did not impair their active antibody responses to concurrently administered diphtheria-tetanus-pertussis or Hib oligo-saccharide-diptheria CRM197conjugate vaccines. In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines.
UR - http://www.scopus.com/inward/record.url?scp=0026632876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026632876&partnerID=8YFLogxK
U2 - 10.1093/infdis/165-Supplement_1-S129
DO - 10.1093/infdis/165-Supplement_1-S129
M3 - Article
C2 - 1588146
AN - SCOPUS:0026632876
SN - 0022-1899
VL - 165
SP - S129
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -